Validating DLL3-targeting CAR T in small cell lung cancer

MD Anderson Delta-Like Ligand 3 (DLL3) is a promising target in small cell lung cancer Leading Edge of Cancer Research Symposium

Median duration of response: 13 months

Tarlatamab - Bi- specific T cell engager (BiTE®) (NCT03392064)

BorghaeiH, WCLC 2022

MD Anderson DLL3 is highly expressed in neuroendocrine subtypes of SCLC Leading Edge of Cancer Research Symposium

DLL3 gene expression in SCLC patient samples

N P I A

N

P

I

A

SCLC subtypes

DLL3 surface expression DLL3 surface expression in SCLC by subtypes

0 20 40 60 80 100

A N P I Subtype

LixiaDiao Yan Yang

Cell line

Gay et al. Cancer Cell 2021

MD Anderson DLL3-targeting CAR T showed robust in-vitro cytotoxicity against SCLC Leading Edge of Cancer Research Symposium

H841

H82 DLL3 high

DLL3 low

0 20 40 60 80 100

0 20 40 60 80 100

DLL3 CAR T in vitro activity (E:T 1:1)

100

A

N P I

DLL3-CAR T

0

Cytotoxicity

Yan Yang

Page 1 Page 2 Page 3

Made with FlippingBook interactive PDF creator